{"id":"ponticelli-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen alternates monthly cycles of intravenous methylprednisolone and cyclophosphamide with oral corticosteroids to induce remission in membranous nephropathy. The cyclophosphamide provides cytotoxic immunosuppression while corticosteroids reduce inflammation, together targeting the autoimmune attack on the glomerular basement membrane.","oneSentence":"The Ponticelli Regimen is an immunosuppressive treatment protocol that combines corticosteroids and cyclophosphamide to suppress immune-mediated kidney damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:01:49.909Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Membranous nephropathy with nephrotic syndrome"}]},"trialDetails":[{"nctId":"NCT05782933","phase":"NA","title":"Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2022-08-04","conditions":"Idiopathic Membranous Nephropathy","enrollment":2},{"nctId":"NCT04424862","phase":"PHASE4","title":"Multitarget Therapy for Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2020-06-09","conditions":"Efficacy","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ponticelli Regimen","genericName":"Ponticelli Regimen","companyName":"Beijing Friendship Hospital","companyId":"beijing-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The Ponticelli Regimen is an immunosuppressive treatment protocol that combines corticosteroids and cyclophosphamide to suppress immune-mediated kidney damage. Used for Membranous nephropathy with nephrotic syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}